Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Zealand Pharma

225.40 DKK-0.84 %15/10 13:59
Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.84 %
-19.12 %
-19.56 %
-23.98 %
-51.67 %
-53.14 %
-29.21 %
+14.01 %
+183.52 %

Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.

Read more
Market cap
16.14B DKK
Turnover
31.36M DKK
Revenue
9.21B
EBIT %
75.52 %
P/E
2.46
Dividend yield-%
-
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Research
Press releases
ShowingAll content types

Financial calendar
12/11
2026

Interim report Q3'26

Regulatory press release2026-10-07 19:13

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma
Regulatory press release2026-10-05 18:30

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma
Regulatory press release2026-10-01 09:30

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-09-30 22:00

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Zealand Pharma
Regulatory press release2026-09-28 17:00

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Zealand Pharma
Regulatory press release2026-09-21 17:00

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Zealand Pharma
Regulatory press release2026-09-14 17:00

Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)

Zealand Pharma
Regulatory press release2026-09-10 17:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Regulatory press release2026-09-07 17:00

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)

Zealand Pharma
Regulatory press release2026-09-02 17:00

Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)

Zealand Pharma
Regulatory press release2026-08-31 17:00

Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)

Zealand Pharma
Regulatory press release2026-08-28 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release2026-08-24 17:05

Zealand Pharma – Notification of holding of treasury shares

Zealand Pharma
Regulatory press release2026-08-24 17:00

Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)

Zealand Pharma
Regulatory press release2026-08-17 17:00

Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)

Zealand Pharma
Analyst Comment2026-08-13 07:19

HCA Red Flag: Zealand Pharma earns BDKK 3.9, but still burns cash (AI)

Expect a weak opening: the pre-tax profit of DKK 4,006 million DKK exceeded the expected MDKK 3,782. DKK alone, because Zealand Pharma spent MDKK 632 DKK vs. 789 MDKK DKK on petrelintide trials that have not yet started. Guidance was maintained, and a royalty sale adds approximately DKK 640M. DKK.

Zealand Pharma
Regulatory press release2026-08-13 07:00

Zealand Pharma Announces Financial Results for the First Half of 2026

Zealand Pharma
Regulatory press release2026-08-12 22:05

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Zealand Pharma
Regulatory press release2026-08-10 17:00

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)

Zealand Pharma
Regulatory press release2026-08-03 17:00

Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)

Zealand Pharma